Research ExplorerPublicationsNY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion ...

NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer

Standard

NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer. / Grupp, Katharina; Ospina-Klinck, Daniel; Tsourlakis, Maria Christina; Koop, Christina; Wilczak, Waldemar; Adam, Meike; Simon, Ronald; Sauter, Guido; Izbicki, Jakob Robert; Graefen, Markus; Huland, Hartwig; Steurer, Stefan; Schlomm, Thorsten; Minner, Sarah; Quaas, Alexander.

In: PROSTATE, Vol. 74, No. 10, 01.07.2014, p. 1012-22.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Grupp, K, Ospina-Klinck, D, Tsourlakis, MC, Koop, C, Wilczak, W, Adam, M, Simon, R, Sauter, G, Izbicki, JR, Graefen, M, Huland, H, Steurer, S, Schlomm, T, Minner, S & Quaas, A 2014, 'NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer', PROSTATE, vol. 74, no. 10, pp. 1012-22. https://doi.org/10.1002/pros.22816

APA

Grupp, K., Ospina-Klinck, D., Tsourlakis, M. C., Koop, C., Wilczak, W., Adam, M., Simon, R., Sauter, G., Izbicki, J. R., Graefen, M., Huland, H., Steurer, S., Schlomm, T., Minner, S., & Quaas, A. (2014). NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer. PROSTATE, 74(10), 1012-22. https://doi.org/10.1002/pros.22816

Vancouver

Grupp K, Ospina-Klinck D, Tsourlakis MC, Koop C, Wilczak W, Adam M et al. NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer. PROSTATE. 2014 Jul 1;74(10):1012-22. https://doi.org/10.1002/pros.22816

Bibtex

@article{c0f1c0c6856e4e5592ddf5588ecc2a88,
title = "NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer",
abstract = "BACKGROUND: NY-ESO-1 has been suggested as therapeutic cancer vaccine in prostate cancer. This study was undertaken to explore the relationship of NY-ESO-1 with tumor phenotype, biochemical recurrence, and molecular subgroups in hormone-naive prostate cancers.METHODS: NY-ESO-1 immunohistochemistry was analyzed on a tissue microarray containing 11,152 prostate cancer samples. Results were compared to clinically follow-up data, ERG status, and deletions on PTEN, 3p13, 5q21, and 6q15.RESULTS: NY-ESO-1 expression was absent in benign prostate glands. In prostate cancer, NY-ESO-1 positivity was found 8.8% of our 8,761 interpretable tumors including 5.8% with weak, 2.5% with moderate, and 0.5% with strong expression. There was a threefold higher rate of NY-ESO-1 expression in ERG fusion positive tumors than in ERG negative cancers (P < 0.0001). There was a significant association with early PSA recurrence, which was largely limited to ERG positive cancers. Within the ERG positive subgroup, high NY-ESO-1 expression was associated with early biochemical recurrence (P = 0.0002) and high Gleason grade (P < 0.0001). In ERG negative cancers, NY-ESO-1 expression was also linked to PTEN (P = 0.0012) and 6q15 deletions (P = 0.0005).CONCLUSIONS: Our observations indicate a tight link of NY-ESO-1 expression to ERG activation and (to a lesser extent) PTEN- and 6q15-deletions in prostate cancer. The impact of these interactions on the likelihood of response to immunotherapy is unclear. The prognostic impact of NY-ESO-1 expression is little and not independent of histologic variables. Prostate 74:1012-1022, 2014. {\textcopyright} 2014 Wiley Periodicals, Inc.",
author = "Katharina Grupp and Daniel Ospina-Klinck and Tsourlakis, {Maria Christina} and Christina Koop and Waldemar Wilczak and Meike Adam and Ronald Simon and Guido Sauter and Izbicki, {Jakob Robert} and Markus Graefen and Hartwig Huland and Stefan Steurer and Thorsten Schlomm and Sarah Minner and Alexander Quaas",
note = "{\textcopyright} 2014 Wiley Periodicals, Inc.",
year = "2014",
month = jul,
day = "1",
doi = "10.1002/pros.22816",
language = "English",
volume = "74",
pages = "1012--22",
journal = "PROSTATE",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "10",

}

RIS

TY - JOUR

T1 - NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer

AU - Grupp, Katharina

AU - Ospina-Klinck, Daniel

AU - Tsourlakis, Maria Christina

AU - Koop, Christina

AU - Wilczak, Waldemar

AU - Adam, Meike

AU - Simon, Ronald

AU - Sauter, Guido

AU - Izbicki, Jakob Robert

AU - Graefen, Markus

AU - Huland, Hartwig

AU - Steurer, Stefan

AU - Schlomm, Thorsten

AU - Minner, Sarah

AU - Quaas, Alexander

N1 - © 2014 Wiley Periodicals, Inc.

PY - 2014/7/1

Y1 - 2014/7/1

N2 - BACKGROUND: NY-ESO-1 has been suggested as therapeutic cancer vaccine in prostate cancer. This study was undertaken to explore the relationship of NY-ESO-1 with tumor phenotype, biochemical recurrence, and molecular subgroups in hormone-naive prostate cancers.METHODS: NY-ESO-1 immunohistochemistry was analyzed on a tissue microarray containing 11,152 prostate cancer samples. Results were compared to clinically follow-up data, ERG status, and deletions on PTEN, 3p13, 5q21, and 6q15.RESULTS: NY-ESO-1 expression was absent in benign prostate glands. In prostate cancer, NY-ESO-1 positivity was found 8.8% of our 8,761 interpretable tumors including 5.8% with weak, 2.5% with moderate, and 0.5% with strong expression. There was a threefold higher rate of NY-ESO-1 expression in ERG fusion positive tumors than in ERG negative cancers (P < 0.0001). There was a significant association with early PSA recurrence, which was largely limited to ERG positive cancers. Within the ERG positive subgroup, high NY-ESO-1 expression was associated with early biochemical recurrence (P = 0.0002) and high Gleason grade (P < 0.0001). In ERG negative cancers, NY-ESO-1 expression was also linked to PTEN (P = 0.0012) and 6q15 deletions (P = 0.0005).CONCLUSIONS: Our observations indicate a tight link of NY-ESO-1 expression to ERG activation and (to a lesser extent) PTEN- and 6q15-deletions in prostate cancer. The impact of these interactions on the likelihood of response to immunotherapy is unclear. The prognostic impact of NY-ESO-1 expression is little and not independent of histologic variables. Prostate 74:1012-1022, 2014. © 2014 Wiley Periodicals, Inc.

AB - BACKGROUND: NY-ESO-1 has been suggested as therapeutic cancer vaccine in prostate cancer. This study was undertaken to explore the relationship of NY-ESO-1 with tumor phenotype, biochemical recurrence, and molecular subgroups in hormone-naive prostate cancers.METHODS: NY-ESO-1 immunohistochemistry was analyzed on a tissue microarray containing 11,152 prostate cancer samples. Results were compared to clinically follow-up data, ERG status, and deletions on PTEN, 3p13, 5q21, and 6q15.RESULTS: NY-ESO-1 expression was absent in benign prostate glands. In prostate cancer, NY-ESO-1 positivity was found 8.8% of our 8,761 interpretable tumors including 5.8% with weak, 2.5% with moderate, and 0.5% with strong expression. There was a threefold higher rate of NY-ESO-1 expression in ERG fusion positive tumors than in ERG negative cancers (P < 0.0001). There was a significant association with early PSA recurrence, which was largely limited to ERG positive cancers. Within the ERG positive subgroup, high NY-ESO-1 expression was associated with early biochemical recurrence (P = 0.0002) and high Gleason grade (P < 0.0001). In ERG negative cancers, NY-ESO-1 expression was also linked to PTEN (P = 0.0012) and 6q15 deletions (P = 0.0005).CONCLUSIONS: Our observations indicate a tight link of NY-ESO-1 expression to ERG activation and (to a lesser extent) PTEN- and 6q15-deletions in prostate cancer. The impact of these interactions on the likelihood of response to immunotherapy is unclear. The prognostic impact of NY-ESO-1 expression is little and not independent of histologic variables. Prostate 74:1012-1022, 2014. © 2014 Wiley Periodicals, Inc.

U2 - 10.1002/pros.22816

DO - 10.1002/pros.22816

M3 - SCORING: Journal article

C2 - 24789172

VL - 74

SP - 1012

EP - 1022

JO - PROSTATE

JF - PROSTATE

SN - 0270-4137

IS - 10

ER -